IMNM(Daily)Technical ChartImmunome Inc.
Formation: Double Bottom + Resisrance Line Breakout + RSI Divergence
Risk management: 1,5%
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.12 USD
−106.81 M USD
14.02 M USD
50.75 M
About Immunome, Inc.
Sector
Industry
CEO
Clay B. Siegall
Website
Headquarters
Bothell
Founded
2006
FIGI
BBG00BR93ZG8
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMNM is 13.26 USD — it has increased by 15.39% in the past 24 hours. Watch Immunome, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immunome, Inc. stocks are traded under the ticker IMNM.
IMNM stock has risen by 43.22% compared to the previous week, the month change is a 7.82% rise, over the last year Immunome, Inc. has showed a 68.91% increase.
We've gathered analysts' opinions on Immunome, Inc. future price: according to them, IMNM price has a max estimate of 38.00 USD and a min estimate of 21.00 USD. Watch IMNM chart and read a more detailed Immunome, Inc. stock forecast: see what analysts think of Immunome, Inc. and suggest that you do with its stocks.
IMNM reached its all-time high on Feb 18, 2021 with the price of 63.78 USD, and its all-time low was 2.09 USD and was reached on May 11, 2022. View more price dynamics on IMNM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IMNM stock is 16.44% volatile and has beta coefficient of 2.80. Track Immunome, Inc. stock price on the chart and check out the list of the most volatile stocks — is Immunome, Inc. there?
Today Immunome, Inc. has the market capitalization of 719.67 M, it has decreased by −4.90% over the last week.
Yes, you can track Immunome, Inc. financials in yearly and quarterly reports right on TradingView.
Immunome, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
IMNM earnings for the last quarter are −0.78 USD per share, whereas the estimation was −0.55 USD resulting in a −41.46% surprise. The estimated earnings for the next quarter are −0.66 USD per share. See more details about Immunome, Inc. earnings.
Immunome, Inc. revenue for the last quarter amounts to 2.91 M USD, despite the estimated figure of 2.29 M USD. In the next quarter, revenue is expected to reach 3.15 M USD.
IMNM net income for the last quarter is −47.10 M USD, while the quarter before that showed −36.12 M USD of net income which accounts for −30.39% change. Track more Immunome, Inc. financial stats to get the full picture.
No, IMNM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 55.00 employees. See our rating of the largest employees — is Immunome, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Immunome, Inc. EBITDA is −309.01 M USD, and current EBITDA margin is −776.16%. See more stats in Immunome, Inc. financial statements.
Like other stocks, IMNM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immunome, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immunome, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immunome, Inc. stock shows the buy signal. See more of Immunome, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.